Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00174369

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00174369. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with non-small cell lung cancer. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies of a tumor and a blood sample will be taken before treatment to examine the how genes affect tumor response to the study medication. Blood samples will be taken to measure the amount of drug in the blood.

Study identification

NCT ID
NCT00174369
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
34 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2005 (Type not available)
Primary completion
Jun 2007 (Actual)
Completion
Jun 2007 (Actual)
Last update posted
Mar 17, 2009

2005 – 2007

United States locations

U.S. sites
14
U.S. states
6
U.S. cities
13
Facility City State ZIP Site status
Pfizer Investigational Site Greenbrae California 94904 —
Pfizer Investigational Site La Jolla California 92037 —
Pfizer Investigational Site La Jolla California 92093 —
Pfizer Investigational Site San Diego California 92103 —
Pfizer Investigational Site San Mateo California 94402 —
Pfizer Investigational Site Tampa Florida 33612 —
Pfizer Investigational Site Ann Arbor Michigan 48106-0995 —
Pfizer Investigational Site Detroit Michigan 48201 —
Pfizer Investigational Site Farmington Hills Michigan 48334 —
Pfizer Investigational Site Coon Rapids Minnesota 55433 —
Pfizer Investigational Site Fridley Minnesota 55432 —
Pfizer Investigational Site Robbinsdale Minnesota 55422 —
Pfizer Investigational Site New York New York 11725 —
Pfizer Investigational Site Philadelphia Pennsylvania 19111 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00174369, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 17, 2009 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.